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Introduction {#jdi13179-sec-0005}
============

The prevalence of type 2 diabetes is increasing worldwide, and it is pathologically involved in accelerating the loss of muscle mass and strength[1](#jdi13179-bib-0001){ref-type="ref"}, [2](#jdi13179-bib-0002){ref-type="ref"}, [3](#jdi13179-bib-0003){ref-type="ref"}. Muscle atrophy is a high‐risk factor for physical disability and mortality[1](#jdi13179-bib-0001){ref-type="ref"}; therefore there is an urgent need to develop effective strategies to prevent and treat diabetes‐related muscle atrophy, including sarcopenia.

Dapagliflozin, a selective sodium--glucose cotransporter 2 inhibitor (SGLT2i), shows glucose‐lowering effects by inhibiting renal glucose reabsorption and increasing urinary glucose excretion[4](#jdi13179-bib-0004){ref-type="ref"}. Reportedly, SGLT2i exerted pleiotropic beneficial effects, such as reduction in bodyweight (BW), fat mass, and other risk factors for cardiovascular and kidney diseases[5](#jdi13179-bib-0005){ref-type="ref"}. Conversely, there are studies reporting that, regarding the effects of SGLT2i on skeletal muscle mass (SMM) in type 2 diabetes patients, SGLT2i significantly reduces muscle mass[6](#jdi13179-bib-0006){ref-type="ref"}, [7](#jdi13179-bib-0007){ref-type="ref"}, whereas others show no significant effect[8](#jdi13179-bib-0008){ref-type="ref"}, [9](#jdi13179-bib-0009){ref-type="ref"}. Accordingly, whether SGLT2i has deleterious, no substantial or beneficial effects on muscle mass remains controversial.

Fibroblast growth factor 21 (FGF21) is an endocrine regulator of glucose and lipid metabolism, and is produced by metabolically active tissues, such as the liver, muscle and adipose tissues[10](#jdi13179-bib-0010){ref-type="ref"}, [11](#jdi13179-bib-0011){ref-type="ref"}. FGF21 targets these tissues, and improves glucose and/or lipid homeostasis[11](#jdi13179-bib-0011){ref-type="ref"}, [12](#jdi13179-bib-0012){ref-type="ref"}; a state of FGF21 resistance has been observed in diabetes, because the circulating levels of FGF21 are elevated, and are correlated to the severity of muscle and hepatic insulin resistance in type 2 diabetes[11](#jdi13179-bib-0011){ref-type="ref"}, [13](#jdi13179-bib-0013){ref-type="ref"}. Therefore, SGLT2i might modulate the function of FGF21 and/or improve the sensitivity of FGF21 in target tissues, thereby leading to the pleiotropic effects on metabolism. Conversely, the potential roles of FGF21 in maintaining SMM have not been validated. The circulating levels of FGF21 are elevated in patients with mitochondrial disorders affecting skeletal muscle[14](#jdi13179-bib-0014){ref-type="ref"}, and FGF21 counteracts muscle stress by enhancing mitochondrial activity[15](#jdi13179-bib-0015){ref-type="ref"}, [16](#jdi13179-bib-0016){ref-type="ref"}. Thus, FGF21 might be involved in regulating SMM and in modulating metabolism. Accordingly, elucidating the effects of SGLT2i on FGF21 in type 2 diabetes would provide novel insights about the influence of SGLT2i on SMM and the mechanisms underlying the pleiotropic effects of SGLT2i.

Myostatin, a myokine mainly produced in skeletal muscle and also in adipose tissue at a low level, negatively regulates muscle growth[17](#jdi13179-bib-0017){ref-type="ref"}, [18](#jdi13179-bib-0018){ref-type="ref"}, [19](#jdi13179-bib-0019){ref-type="ref"}. Myostatin secreted into the circulation reflects its intramuscular levels[20](#jdi13179-bib-0020){ref-type="ref"}, [21](#jdi13179-bib-0021){ref-type="ref"}, [22](#jdi13179-bib-0022){ref-type="ref"}, and acts systemically to bind its receptors, causing muscle loss[23](#jdi13179-bib-0023){ref-type="ref"}. As skeletal muscle functions as the major site of insulin‐mediated glucose uptake, wasting muscle would aggravate insulin resistance, which would further lead to exacerbation of diabetes and cause diabetes‐related muscle loss[3](#jdi13179-bib-0003){ref-type="ref"}. In addition, skeletal muscle produces both myostatin and FGF21; thus, a functional cross‐talk might exist between these regulators. In patients with type 2 diabetes, a previous study reported that circulating myostatin levels were negatively associated with levels of fasting plasma glucose and triglycerides[24](#jdi13179-bib-0024){ref-type="ref"}, whereas another study observed no significant metabolic effect of circulating myostatin[25](#jdi13179-bib-0025){ref-type="ref"}. Therefore, the clinical significance of circulating myostatin on glucose metabolism and muscle mass, and the effects of SGLT2i on myostatin in type 2 diabetes have not been fully elucidated.

Preclinical studies have shown that myostatin also plays a role in modulating the function of adipose tissue[26](#jdi13179-bib-0026){ref-type="ref"}. Myostatin is involved in suppressing the secretion of irisin by the muscle and another myokine, which enhances energy expenditure through the process of browning white adipose tissues[27](#jdi13179-bib-0027){ref-type="ref"}, [28](#jdi13179-bib-0028){ref-type="ref"}, and FGF21 enhances the irisin‐induced browning process[29](#jdi13179-bib-0029){ref-type="ref"}, [30](#jdi13179-bib-0030){ref-type="ref"}. Most circulating irisin is derived from muscle in healthy conditions, but adipose tissue actively secretes irisin in body mass index (BMI)‐atypical settings, such as obesity[31](#jdi13179-bib-0031){ref-type="ref"}. In patients with type 2 diabetes, conversely, circulating levels of irisin were lower than in control individuals[28](#jdi13179-bib-0028){ref-type="ref"}. Thus, the pathophysiological significance of irisin in disease conditions remains complex.

As FGF21 and myostatin have positive and negative regulatory effects, respectively, on the irisin‐induced browning process[27](#jdi13179-bib-0027){ref-type="ref"}, [28](#jdi13179-bib-0028){ref-type="ref"}, [29](#jdi13179-bib-0029){ref-type="ref"}, [30](#jdi13179-bib-0030){ref-type="ref"}, a cross‐talk might exist between these regulators. Thus, the pleiotropic effects of SGLT2i might be correlated to the functions of these endocrine/metabolic regulators. We recently reported the potential pathological implications of circulating myostatin in regulating muscle mass and glucose metabolism in obese patients, using a cohort of Japanese patients with obesity and/or diabetes[32](#jdi13179-bib-0032){ref-type="ref"}. In the present study based on this cohort, we investigated the add‐on effects of dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, and on the levels of FGF21, myostatin and irisin in patients with type 2 diabetes.

Methods {#jdi13179-sec-0006}
=======

Study design {#jdi13179-sec-0007}
------------

This was a 24‐week, two‐arm, randomized, open‐label, active‐controlled, blinded end‐point trial. This study was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN‐CTR) system (ID: UMIN000021479). Approval for the study was obtained from the ethics committee for human research at Kyoto Medical Center (approval number: 15‐109). The study was carried out in accordance with the principles of the Declaration of Helsinki and the *Ethical Guidelines for Medical and Health Research Involving Human Subjects*. All participants provided written informed consent. Appendix [S1](#jdi13179-sup-0002){ref-type="supplementary-material"} shows the CONSORT 2010 checklist for this trial.

Participants {#jdi13179-sec-0008}
------------

The participants were screened from a cohort of Japanese diabetes patients enrolled in the outpatient clinic of the National Hospital Organization Kyoto Medical Center between November 2016 and June 2018. Eligible individuals were patients aged 20--79 years with type 2 diabetes; who had a hemoglobin A~1c~ (HbA~1c~) level of ≥6.5% to \<9.0% and a BMI of ≥22 kg/m^2^; and who were receiving diet and exercise therapy, and taking sulfonylurea, biguanide, α‐glucosidase inhibitor or dipeptidyl peptidase‐4 inhibitors or their combinations. The exclusion criteria were secondary obesity associated with endocrine disorders; type 1 diabetes; severe ketosis; diabetic coma or precoma; severe infectious disease; being in the period before or after surgery; external injury; severe hepatic dysfunction; serum creatinine ≥1.5 mg/dL (men) or ≥1.3 mg/dL (women); a history of severe vascular disease in the previous 6 months (including myocardial infarction and stroke); dehydration or diarrhea that would cause dehydration; taking thiazolidinediones and/or fibrate; taking SGLT2is, insulin formulations or GLP‐1 receptor agonists; pregnancy or lactation; a history of hypersensitivity to SGLT2i; and findings suggestive of ineligibility by an attending doctor.

Randomization and masking {#jdi13179-sec-0009}
-------------------------

The participants were centrally randomized at the SATISTA Co., Ltd. (Kyoto, Japan), a site external to the trial, and assigned to the control or dapagliflozin group in a 1:1 allocation ratio, through computer‐generated random number and assignment tables. Allocation was carried out using random permuted blocks of size four. Stratification factors were based on the patient's age, HbA~1c~ level and medications at baseline. During the randomization procedure, no content was disclosed to the clinical staff or assessors, whereas this was an open‐label trial, and the physicians and patients recognized the type of medication used.

Intervention {#jdi13179-sec-0010}
------------

The dapagliflozin group received once‐daily 5 mg dapagliflozin in addition to their conventional type 2 diabetes medications. The control group simply took their conventional medications for type 2 diabetes. Combination‐restrictive medicines included biguanides, sulfonylurea drugs, α‐glucosidase inhibitors and dipeptidyl peptidase‐4 inhibitors. If there should be unfavorable effects, such as side‐effects, the medications would be reduced or stopped and shifted to more appropriate treatments, according to the attending physician's judgment. There was no restriction on multimodal treatments, such as diet and exercise therapies. Diuretics and biguanides were to be reduced or stopped if symptoms of dehydration should be observed or expected.

Outcomes and measurements {#jdi13179-sec-0011}
-------------------------

The primary outcome was changed in the level of serum FGF21 from baseline to 12 and 24 weeks after administration. The secondary outcomes were changes from baseline to 12 and 24 weeks in anthropometric/metabolic parameters, and serum levels of myostatin and irisin.

Anthropometric and metabolic parameters were measured for all patients, and blood samples were taken between 08.30 hours and 09.30 hours after overnight fasting (baseline), and after 12 and 24 weeks of intervention, using standard procedures[32](#jdi13179-bib-0032){ref-type="ref"}, [33](#jdi13179-bib-0033){ref-type="ref"}, [34](#jdi13179-bib-0034){ref-type="ref"}. The anthropometric parameters included BW, BMI, waist circumference, muscle thickness, SMM, visceral fat mass and subcutaneous fat mass. The metabolic parameters included systolic and diastolic blood pressure, fasting plasma glucose, HbA~1c~, serum immunoreactive insulin, homeostasis model assessment of insulin resistance, triglycerides, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, γ‐glutamyl transpeptidase (γ‐GTP) and estimated glomerular filtration rate.

We measured SMM and body water within 2 weeks of blood sample collection, using a precision body composition analyzer (InBody720; InBody Japan Inc., Tokyo, Japan)[32](#jdi13179-bib-0032){ref-type="ref"}, [35](#jdi13179-bib-0035){ref-type="ref"}. Intra‐abdominal fat area (IFA) and subcutaneous fat area (SFA) were measured with dual bioelectrical impedance analysis using DUALSCAN HDS‐2000 (Omron Healthcare Corporation, Kyoto, Japan)[32](#jdi13179-bib-0032){ref-type="ref"}, [36](#jdi13179-bib-0036){ref-type="ref"} on the same day as that of SMM measurement.

Serum levels of FGF21, myostatin and irisin were measured at Health Sciences West Japan (Kyoto, Japan) using a Human FGF‐21 Quantikine ELISA Kit (DF2100; R&D Systems, Minneapolis, MN, USA), a GDF‐8/Myostatin Quantikine ELISA Kit (DGDF80; R&D Systems) and a Human FNDC5/Irisin ELISA Kit (sandwich ELISA; LS‐F38053; LifeSpan BioSciences, Seattle, WA, USA), respectively, according to the manufacturer's instructions. We measured each serum sample in duplicate and used average values for analysis.

Statistical analysis {#jdi13179-sec-0012}
--------------------

In a previous study, changes in serum FGF21 levels within each participant were normally distributed with a standard deviation of 60[37](#jdi13179-bib-0037){ref-type="ref"}. If the true difference in the intervention and control means is 50 (intervention group, +50 ± 60 ng/L; control group, 0 ± 60 ng/L), we need to study 24 intervention participants and 24 control participants to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) of 80%. The type I error probability associated with this test of this null hypothesis is 0.05. Finally, in anticipation of a dropout rate of 20%, the sample size was set at 60 participants.

The results are described as the mean ± standard deviation or median (interquartile range). We applied a logarithmic transformation to variables with a lognormal distribution. Two‐way repeated‐measures analysis of covariance ([ancova]{.smallcaps}) was applied to evaluate between‐group differences in outcomes at 12 or 24 weeks compared with 0 weeks (baseline), in which time and group, as well as the interaction between time and group, were the categorical fixed factors. Then, for a significant variable identified by [ancova]{.smallcaps}, a two‐tailed, paired *t*‐test was applied to evaluate the changes in conditions between baseline and end of treatment. The results are shown as within‐ or between‐group differences with 95% confidence intervals. Effects were evaluated on an intention‐to‐treat basis, and we considered participants who did not complete the follow‐up period as not to have had any changes in measures. If levels of regulators (FGF21, myostatin and irisin) were significantly changed in the dapagliflozin group compared with the control group, Pearson's correlation coefficient (*r*) was used to investigate the correlations between the changes in the levels of the regulators and the changes in anthropometric/metabolic parameters. A two‐sided *P*‐value \<0.05 was considered to show statistical significance. The statistical analyses were carried out using SPSS version 23.0 for Windows (IBM Japan Ltd., Tokyo, Japan).

Results {#jdi13179-sec-0013}
=======

Study flow {#jdi13179-sec-0014}
----------

Figure [1](#jdi13179-fig-0001){ref-type="fig"} outlines the trial. A total of 60 patients were screened from November 2016 to June 2018, and 54 were randomly assigned to receive either dapagliflozin 5 mg/day in addition to conventional treatment for type 2 diabetes (dapagliflozin group) or conventional treatment for type 2 diabetes without dapagliflozin (control group; *n* = 27 each). In the dapagliflozin arm, 26 patients completed the study, with one dropping out because of study medication‐related complications. In the control arm, 24 patients completed the study, with one withdrawing and two having a scheduling conflict. There were no differences in background characteristics between participants who completed the study and those who discontinued. None of the participants in either group required treatment modifications, including the currently used oral hypoglycemic agents, during the study period.

![Patient flowchart for screening, randomization and completion of the 24‐week evaluation.](JDI-11-653-g001){#jdi13179-fig-0001}

Baseline characteristics {#jdi13179-sec-0015}
------------------------

Table [1](#jdi13179-tbl-0001){ref-type="table"} shows the baseline characteristics of the participants (*n* = 54). The characteristics at baseline were balanced between the dapagliflozin and control groups.

###### 

Characteristics of the two groups at baseline

  Characteristic                         Dapagliflozin group     Control group
  -------------------------------------- ----------------------- ----------------------
  *n*                                    27                      27
  Sex, *n* (%)                                                   
  Male                                   11, 40.7                14, 51.9
  Female                                 16, 59.3                13, 48.1
  Age (years)                            58.4 ± 13.0             60.7 ± 11.9
  BMI (kg/m^2^)                          31.3 ± 7.6              30.7 ± 6.2
  Waist circumference (cm)               102.2 ± 17.9            103.2 ± 14.2
  IFA (cm^2^)                            101.4 ± 28.0            110.5 ± 39.8
  SFA (cm^2^)                            254.4 ± 81.0            223.8 ± 60.7
  Skeletal muscle mass (kg)              25.9 ± 6.7              27.1 ± 6.3
  Skeletal muscle mass‐to‐BW ratio (%)   32.7 ± 5.3              35.0 ± 5.3
  Muscle thickness (mm)                  12.2 ± 4.0              12.2 ± 2.6
  Body water (L)                         34.9 ± 8.3              36.8 ± 7.7
  SBP (mmHg)                             134.6 ± 13.2            132.9 ± 11.9
  DBP (mmHg)                             80.0 ± 9.3              78.6 ± 7.8
  FPG (mmol/L)                           8.5 ± 2.7               8.1 ± 2.0
  HbA~1c~ (%)                            7.5 ± 0.8               7.4 ± 0.9
  HbA~1c~ (mmol/mol)                     58.3 ± 8.5              57.7 ± 9.9
  IRI (pmol/L)                           111.3 \[59.5--145.6\]   73.2 \[58.3--125.5\]
  HOMA‐IR                                2.8 \[2.2--4.2\]        3.4 \[2.5--6.0\]
  Triglycerides (mmol/L)                 1.5 \[1.1--1.9\]        1.5 \[1.2--2.6\]
  HDL‐C (mmol/L)                         1.3 ± 0.2               1.4 ± 0.5
  LDL‐C (mmol/L)                         3.0 ± 0.6               2.8 ± 0.7
  AST (units/L)                          31.0 ± 16.4             28.9 ± 12.4
  ALT (units/L)                          38.3 ± 27.3             32.4 ± 16.5
  γ‐GTP (units/L)                        50.6 ± 54.3             58.1 ± 71.5
  eGFR (mL/min/1.73 m^2^)                76.2 ± 18.0             73.0 ± 24.8
  Diabetes treatment, *n* (%)                                    
  SU                                     11, 40.7                9, 33.3
  α‐GI                                   1, 3.7                  3, 11.1
  BG                                     22, 81.5                17, 63.0
  DPP‐4                                  19, 70.4                19, 70.4

Data are expressed as the mean ± standard deviation, median \[interquartile range\], or the number and percentage of patients. α‐GI, α‐glucosidase inhibitor; γ‐GTP, γ‐glutamyl transpeptidase; ALT, alanine amino transferase; AST, aspartate aminotransferase; BG, biguanide; DBP, diastolic blood pressure; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA~1c~, hemoglobin A~1c~; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐R, homeostasis model assessment of insulin resistance; IFA, intra‐abdominal fat area; IRI, immunoreactive insulin; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; SFA, subcutaneous fat area; SU, sulfonylurea.
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Effects of dapagliflozin add‐on therapy on primary and secondary outcomes {#jdi13179-sec-0016}
-------------------------------------------------------------------------

Table [2](#jdi13179-tbl-0002){ref-type="table"} summarizes the changes in the primary and secondary outcomes from baseline to the middle (12 weeks) and end (24 weeks) of the intervention in the dapagliflozin and control groups.

###### 

Changes in primary and secondary outcomes

  Outcome               Time                  Mean change from baseline   Between‐group difference             
  --------------------- --------------------- --------------------------- -------------------------- --------- ---
  FGF21 (pg/mL)         Baseline              209.8 ± 101.4               259.4 ± 209.5                         
  Week 12               183.8 ± 85.2          248.0 ± 176.5                                                    
  Week 24               226.3 ± 230.7         265.1 ± 180.0                                                    
  Δ (95% CI)            16.5 (−62.8, 95.8)    5.7 (−46.2, 57.6)           10.8 (−81.8, 103.3)        0.816     
  Myostatin (pg/mL)     Baseline              3,745 ± 1,970               3,804 ± 1,651                         
  Week 12               3,157 ± 1,493         3,825 ± 1,877                                                    
  Week 24               3,143 ± 1,546         4,117 ± 1,772                                                    
  Δ (95% CI)            −601 (−1,223, 21)     314 (−8, 635)               −915 (−1,599, −231)        0.010     
  Irisin (ng/mL)        Baseline              93.3 ± 82.3                 100.6 ± 74.8                          
  Week 12               63.2 ± 62.8           101.4 ± 84.4                                                     
  Week 24               61.1 ± 57.9           94.3 ± 72.2                                                      
  Δ (95% CI)            −32.3 (−55.5. −9.0)   −6.4 (−19.7, 6.9)           −25.9 (−52.1, 0.26)        0.052     
  HbA1c (%)             Baseline              7.5 ± 0.8                   7.4 ± 0.9                             
  Week 12               7.0 ± 0.6             7.3 ± 0.9                                                        
  Week 24               6.8 ± 0.5             7.6 ± 1.0                                                        
  Δ (95% CI)            −0.6 (−0.9, −0.4)     0.2 (−0.2, 0.4)             −0.8 (−1.3, −0.3)          0.001     
  BW (kg)               Baseline              80.5 ± 22.6                 79.0 ± 16.3                           
  Week 12               78.3 ± 22.8           78.9 ± 16.3                                                      
  Week 24               77.3 ± 22.0           79.0 ± 15.7                                                      
  Δ (95% CI)            −3.2 (−4.1, −2.4)     0.0 (−1.0, 1.0)             −3.2 (−4.5, −2.0)          \<0.001   
  BMI                   Baseline              31.3 ± 7.6                  30.7 ± 6.2                            
  Week 12               30.4 ± 7.7            30.7 ± 6.3                                                       
  Week 24               30.0 ± 7.4            30.7 ± 6.0                                                       
  Δ (95% CI)            −1.2 (−1.6, −0.9)     0.0 (−0.4, 0.4)             −1.3 (−1.8, −0.8)          \<0.001   
  IFA (cm^2^)           Baseline              101.4 ± 28.0                110.5 ± 39.8                          
  Week 12               90.9 ± 26.3           112.3 ± 42.2                                                     
  Week 24               91.5 ± 28.7           114.0 ± 46.4                                                     
  Δ (95% CI)            −9.8 (−17.7, −2.0)    3.5 (−3.5, 10.5)            −13.3 (−23.4, −3.2)        0.009     
  SFA (cm^2^)           Baseline              254.4 ± 81.0                223.8 ± 60.7                          
  Week 12               243.8 ± 79.6          229.0 ± 59.4                                                     
  Week 24               238.1 ± 74.8          237.1 ± 68.1                                                     
  Δ (95% CI)            −16.3 (−31.2, −1.4)   13.3 (−7.9, 34.5)           −29.6 (−55.2, −4.0)        0.025     
  SMM (kg)              Baseline              25.9 ± 6.7                  27.1 ± 6.3                            
  Week 12               26.1 ± 6.7            27.2 ± 6.4                                                       
  Week 24               26.0 ± 7.4            26.9 ± 6.1                                                       
  Δ (95% CI)            0.1 (−1.0. 1.2)       −0.2 (−0.4, 0.1)            0.3 (−0.9, 1.4)            0.611     
  SMM‐to‐BW ratio (%)   Baseline              32.7 ± 5.3                  35.0 ± 5.3                            
  Week 12               34.1 ± 6.1            35.3 ± 5.5                                                       
  Week 24               34.3 ± 7.1            34.8 ± 5.4                                                       
  Δ (95% CI)            1.6 (0.1, 3.1)        −0.2 (−0.7, 0.3)            1.8 (0.2, 3.4)             0.028     
  Body water (L)        Baseline              34.9 ± 8.3                  36.8 ± 7.7                            
  Week 12               35.2 ± 8.2            37.0 ± 7.8                                                       
  Week 24               35.0 ± 9.3            36.7 ± 7.5                                                       
  Δ (95% CI)            0.1 (−1.7, 1.5)       −0.1 (−0.2, 0.5)            0.2 (−1.4, 1.8)            0.787     

Δ Represents the difference between the 24‐week and baseline values. "Between‐group difference" indicates the difference between the dapagliflozin group and the control group values. *P*‐values from two‐way repeated‐measures [ancova]{.smallcaps} (time \[baseline and at 24 weeks\] × group \[dapagliflozin and control\]). 95% CI, 95% confidence interval; α‐GI, α‐glucosidase inhibitor; γ‐GTP, γ‐glutamyl transpeptidase; ALT, alanine amino transferase; AST, aspartate aminotransferase; BG, biguanide; DBP, diastolic blood pressure; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA~1c~, hemoglobin A~1c~; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment of insulin resistance; IFA, intra‐abdominal fat area; IRI, immunoreactive insulin; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; SFA, subcutaneous fat area; SU, sulfonylurea.

John Wiley & Sons, Ltd

Serum levels of FGF21 did not differ significantly between baseline and the end of the intervention in either group (dapagliflozin group, *P* = 0.673; control group, *P* = 0.823). There were also no significant differences in the changes between the groups (*P* = 0.816). The serum level of myostatin decreased in the dapagliflozin group from baseline to the end of the intervention (*P* = 0.052), but increased to a nearly significant extent in the control group (*P* = 0.066). There was a significant difference between the groups in the changes in myostatin levels (*P* = 0.010). Serum levels of irisin were reduced in the dapagliflozin group (*P* = 0.039), but unchanged in the control group (*P* = 0.200). There was a nearly significant difference between the groups in the changes in irisin levels (*P* = 0.052).

The dapagliflozin group had a significant reduction in HbA~1c~ values from baseline to the end of the intervention (*P* \< 0.001), but the control group had no significant change (*P* = 0.391), leading to a significant difference between the groups in the changes in HbA~1c~ values (*P* = 0.001). BW was reduced in the dapagliflozin group (*P* \< 0.001), but not in the control group (*P* = 0.997), which resulted in a significant difference between the groups in BW changes (*P* \< 0.001). BMI was decreased in the dapagliflozin group (*P* \< 0.001), but not in the control group (*P* = 0.954), and there was a significant difference between the groups in BMI changes (*P* \< 0.001). We further found a significant reduction in IFA in the dapagliflozin group (*P* = 0.028), but no significant change in the control group (*P* = 0.695); there was a significant difference between the groups in IFA changes (*P* = 0.009). Similarly, SFA was decreased in the dapagliflozin group (*P* = 0.034), but not changed in the control group (*P* = 0.205), and the difference in SFA changes between the groups was significant (*P* = 0.025). SMM remained unchanged in both groups (dapagliflozin group, *P* = 0.975; control group, *P* = 0.121), and there was no significant difference between the groups in SMM changes (*P* = 0.611).

We found a significant increase and no significant change in the SMM‐to‐BW ratio values from baseline to the end of the intervention in the dapagliflozin (*P* = 0.047) and control (*P* = 0.408) groups, respectively. There was a significant difference between the groups in the changes in the SMM‐to‐BW ratio values (*P* = 0.028).

As we observed significant changes in myostatin levels (*P* = 0.010) and SMM‐to‐BW ratio values (*P* = 0.028) between the dapagliflozin and control groups, we further analyzed the relationship between the changes in myostatin levels and the changes in SMM‐to‐BW ratio values in these groups. Among all patients, the changes in myostatin levels showed a significant negative correlation with the changes in SMM‐to‐BW ratio values (*r* = −0.334, *P* = 0.020). Furthermore, there was an almost significant negative correlation between the changes in myostatin levels and the changes in SMM‐to‐BW ratio values in the dapagliflozin group (*r* = −0.331, *P* = 0.122), whereas this was not seen in the control group (*r* = −0.062, *P* = 0.783).

Body water did not change significantly from baseline to the end of the intervention in the dapagliflozin (*P* = 0.900) and control (*P* = 0.465) groups. There was also no significant difference between the groups in the changes in body water (*P* = 0.787).

Table [S1](#jdi13179-sup-0001){ref-type="supplementary-material"} shows the changes in markers of liver function. Aspartate aminotransferase values did not change significantly from baseline to the end of the intervention in both the dapagliflozin group (*P* = 0.183) and the control group (*P* = 0.218), and the changes in aspartate aminotransferase values did not significantly differ between the groups (*P* = 0.071). ALT values remained unchanged between baseline and the end of intervention in the dapagliflozin (*P* = 0.429) and control (*P* = 0.212) groups, and there was no significant difference between the groups in the changes in ALT values (*P* = 0.203). γ‐GTP values decreased to a nearly significant extent in the dapagliflozin group (*P* = 0.068), but did not change in the control group (*P* = 0.184). There was a significant difference between the groups in the changes in γ‐GTP values (*P* = 0.034).

Adverse events {#jdi13179-sec-0017}
--------------

Five adverse events were reported by two patients after randomization. No patient had a serious adverse event requiring hospitalization. One patient in the dapagliflozin group developed dehydration within 1 day of initiation of the drug. The drug was discontinued, and the symptoms improved. One patient in the control group developed hunger, dizziness and cramps within 1 day of initiation of the drug, and finger tumor deterioration within 20 weeks of initiation of the drug.

Discussion {#jdi13179-sec-0018}
==========

This is the first study to examine the mechanisms underlying the pleiotropic beneficial effects of SGLT2i by investigating the regulators of the endocrine system (FGF21), SMM (myostatin) and metabolism (irisin). We showed that dapagliflozin add‐on therapy did not significantly affect the circulating levels of FGF21, but decreased those of myostatin and irisin to a significant and nearly significant extent, respectively, in patients with type 2 diabetes. Furthermore, dapagliflozin maintained SMM, in parallel with reducing HbA~1c~, BW, BMI, IFA and SFA, which led to the elevation of SMM‐to‐BW ratios. Accordingly, these findings suggest that dapagliflozin decreases myostatin production, thereby contributing to reducing the risk of muscle loss in type 2 diabetes patients.

In the present study, dapagliflozin did not significantly affect the circulating levels of FGF21, but markedly decreased those of myostatin. Therefore, dapagliflozin does not cause pleiotropic effects through direct modulation of the circulating levels of FGF21, and FGF21 and myostatin could function independently of each other. However, dapagliflozin improved glucose metabolism and the SMM‐to‐BW ratio; thus, it concomitantly contributed in restoring the sensitivity of FGF21 in target tissues, thereby indirectly enhancing the metabolic effects of FGF21. Notably, regarding the maintenance of SMM, a recent study that used FGF21 knockout mice reported that FGF21 induced muscle loss through mytophagy[38](#jdi13179-bib-0038){ref-type="ref"}. Although further study must be carried out to elucidate the functional significance of FGF21 in maintaining SMM in patients with type 2 diabetes, the present results showed that dapagliflozin had a beneficial effect on the SMM‐to‐BW ratio. Although FGF21 can have detrimental effects on SMM in type 2 diabetes patients, dapagliflozin could counteract these effects.

There has been a controversy about the effects of SGLT2i on muscle mass, and the effects of SGLT2i on myostatin have not been determined. Here, dapagliflozin significantly reduced circulating levels of myostatin in type 2 diabetes patients. Reportedly, diabetes/obesity‐related factors, such as hyperglycemia and palmitate, activate myostatin expression, which would cause muscle wasting[39](#jdi13179-bib-0039){ref-type="ref"}. In the present study, dapagliflozin improved glucose metabolism, fat mass and BMI, in parallel with reducing myostatin levels. Adipose tissue produces myostatin, but its level is limited compared with that of muscle[17](#jdi13179-bib-0017){ref-type="ref"}, and dapagliflozin did not significantly reduce muscle mass in the present study. Accordingly, loss of myostatin‐producing tissues would have a minor role in reducing the myostatin levels observed in this study; rather, dapagliflozin showed beneficial effects on glucose metabolism and fat mass, which would consequently reduce myostatin levels by alleviating intramuscular pathways involved in myostatin production. These results therefore imply qualitative improvements of muscle, which represent potential novel benefits of dapagliflozin in reducing the risk of muscle atrophy in type 2 diabetes patients.

Previous preclinical studies reported that myostatin inactivation led to irisin elevation[27](#jdi13179-bib-0027){ref-type="ref"}, [28](#jdi13179-bib-0028){ref-type="ref"}. However, in the present study, irisin levels were not increased by dapagliflozin (but rather were decreased), despite the reduction in myostatin levels. Muscle is a main producer of irisin in healthy conditions, whereas adipose tissue actively elevates irisin in atypical BMI settings, such as obesity[31](#jdi13179-bib-0031){ref-type="ref"}. Accordingly, the decrease in irisin levels might be attributable to dapagliflozin‐mediated reduction of fat mass. Dapagliflozin did not significantly affect FGF21 levels. Thus, whether dapagliflozin is involved in the enhancement of the irisin‐induced browning process by FGF21 remains unclear, and further investigations must be carried out to address this issue.

SGLT2i is reportedly involved in reducing liver fat and ALT levels in patients with type 2 diabetes and non‐alcoholic fatty liver disease[40](#jdi13179-bib-0040){ref-type="ref"}, [41](#jdi13179-bib-0041){ref-type="ref"}. Although the mechanistic details underlying the beneficial effects of SGLT2i on liver function have not been clarified, a preclinical study found deleterious effects of myostatin on hepatocytes, such as inhibition of proliferation and insulin‐stimulated glucose uptake[42](#jdi13179-bib-0042){ref-type="ref"}. The present study confirmed that dapagliflozin reduced myostatin levels and improved γ‐GTP levels compared with control treatment in type 2 diabetes patients. Accordingly, dapagliflozin‐mediated reduction in myostatin levels could contribute to improving liver function as well, in addition to maintaining muscle mass, in type 2 diabetes patients.

The present study had some limitations. First, this was an open‐label design, and the physicians and patients recognized the type of medications used, which might have caused unintentional bias. Second, the study addressed changes in muscle mass, but changes in muscle power and function remain unclear. Investigating sarcopenia‐related markers, such as grip strength, would be helpful for a comprehensive understanding of the effects of SGLT2i on muscle. Additionally, the changes before and after intervention in the activation levels of myostatin signaling or insulin signaling in muscle, liver and adipose tissue remain to be elucidated. The activation levels of FGF21 signaling in these tissues also remain unclear. Experimental studies using biopsies and model mice would be critical to address these issues.

In conclusion, the present study has provided the first evidence showing that dapagliflozin add‐on therapy maintained the levels of FGF21, and reduced those of myostatin and irisin to a significant and nearly significant extent, respectively, in patients with type 2 diabetes. These findings imply that dapagliflozin beneficially affects intramuscular signaling, potentially by improving glucose homeostasis and fat mass; this would contribute to reducing the risk of muscle loss and improving FGF21 sensitivity in type 2 diabetes patients. Future studies to elucidate the mechanistic details underlying the effects of SGLT2i on muscle would be helpful to develop novel strategies for preventing and treating muscle atrophy in type 2 diabetes.
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